PepGen crashes after mid-stage trial data for muscle disorder therapy
Source: SeekingAlpha
2026-03-31 06:56:54 ET
More on PepGen
- PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data - Slideshow
- PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript
- PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines
- Biggest stock movers: SPCE, MKC, and more
- PepGen slides on FDA partial hold on mid-stage trial for lead asset
Read the full article on Seeking Alpha
For further details see:
PepGen crashes after mid-stage trial data for muscle disorder therapy
PepGen Inc.
NASDAQ: PEPG
PEPG Trading
-3.78% G/L:
$1.40 Last:
203,413 Volume:
$1.48 Open:
PEPG Latest News
May 21, 2026 07:00:00 am
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 12, 2026 04:05:00 pm
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
March 30, 2026 04:05:00 pm
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
March 04, 2026 04:05:00 pm
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PEPG Stock Data
$378,802,714
40,177,150
1.23%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
